Lupus & antiphospholipid syndrome
Efficacy and safety of telitacicept combined with standard of care in patients with proliferative lupus nephritis: a real-world retrospective study
Authors' conclusion
This real-world study demonstrates that telitacicept combined with SoC significantly improves renal response rates during the induction phase of proliferative LN while reducing glucocorticoid exposure.
Study context
- Population
- Patients with biopsy-proven ISN/RPS Class III/IV (with or without Class V) lupus nephritis (LN); induction therapy
- Participants
- 112 patients
- Exposure
- Telitacicept plus standard of care (SoC) vs SoC alone
- Telitaciceptn = 56
- Controln = 56reference
- Outcome
- Rates of complete renal response (CR) and partial renal response (PR)
- Follow-up
- Week 24
Methodological detailsreal-world, propensity score-based inverse probability of treatment weighting (IPTW)
- Real-world
- Propensity score-based IPTW
Main finding
As reported in the abstract
Values · week 24
PR rate
- Telitacicept vs Control: P = 0.004
- Telitacicept vs Control: P = 0.023
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Achieving CR (multivariate Cox regression)Independent predictor | 4.43 (2.25–8.73) | P < 0.001 | |
| 0.10.31310Hazard ratio (log scale) |
Disease activity markers, GC dosages, SLEDAI-2K, BILAG and PGA
- Significant improvements in serum albumin, 24-hour urinary protein and urinary leucocyte and erythrocyte counts with telitacicept
- GC dosages, SLEDAI-2K, BILAG and PGA scores significantly reduced with telitacicept
Original publication
Efficacy and safety of telitacicept combined with standard of care in patients with proliferative lupus nephritis: a real-world retrospective study. Lupus Sci Med. Published 12 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →